A Reevaluation of the Voluntary Medical Male Circumcision Scale-Up Plan in Zimbabwe

被引:25
作者
Awad, Susanne F. [1 ]
Sgaier, Sema K. [2 ,3 ]
Ncube, Gertrude [4 ]
Xaba, Sinokuthemba [4 ]
Mugurungi, Owen M. [4 ]
Mhangara, Mutsa M. [4 ]
Lau, Fiona K. [2 ]
Mohamoud, Yousra A. [1 ]
Abu-Raddad, Laith J. [1 ,5 ,6 ]
机构
[1] Cornell Univ, Qatar Fdn, Weill Cornell Med Coll Qatar, Infect Dis Epidemiol Grp, Doha, Qatar
[2] Bill & Melinda Gates Fdn, Global Dev Program, Integrated Delivery, Seattle, WA USA
[3] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA
[4] Minist Hlth & Child Care, AIDS & TB Programme, Harare, Zimbabwe
[5] Cornell Univ, Dept Healthcare Policy & Res, Weill Cornell Med Coll, New York, NY 10021 USA
[6] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA
基金
比尔及梅琳达.盖茨基金会;
关键词
MODELS;
D O I
10.1371/journal.pone.0140818
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background The voluntary medical male circumcision (VMMC) program in Zimbabwe aims to circumcise 80% of males aged 13-29 by 2017. We assessed the impact of actual VMMC scale-up to date and evaluated the impact of potential alterations to the program to enhance program efficiency, through prioritization of subpopulations. Methods and Findings We implemented a recently developed analytical approach: the age-structured mathematical (ASM) model and accompanying three-level conceptual framework to assess the impact of VMMC as an intervention. By September 2014, 364,185 males were circumcised, an initiative that is estimated to avert 40,301 HIV infections by 2025. Through age-group prioritization, the number of VMMCs needed to avert one infection (effectiveness) ranged between ten (20-24 age-group) and 53 (45-49 age-group). The cost per infection averted ranged between $ 811 (20-24 age-group) and $ 5,518 (45-49 age-group). By 2025, the largest reductions in HIV incidence rate (up to 27%) were achieved by prioritizing 10-14, 1519, or 20-24 year old. The greatest program efficiency was achieved by prioritizing 15-24, 15-29, or 15-34 year old. Prioritizing males 13-29 year old was programmatically efficient, but slightly inferior to the 15-24, 15-29, or 15-34 age groups. Through geographic prioritization, effectiveness varied from 9-12 VMMCs per infection averted across provinces. Through risk-group prioritization, effectiveness ranged from one (highest sexual risk-group) to 60 (lowest sexual risk-group) VMMCs per infection averted. Conclusion The current VMMC program plan in Zimbabwe is targeting an efficient and impactful age bracket (13-29 year old), but program efficiency can be improved by prioritizing a subset of males for demand creation and service availability. The greatest program efficiency can be attained by prioritizing young sexually active males and males whose sexual behavior puts them at higher risk for acquiring HIV.
引用
收藏
页数:16
相关论文
共 25 条
[1]  
[Anonymous], DEM HLTH SURV
[2]  
[Anonymous], ZIMB DEM HLTH SURV 2
[3]  
[Anonymous], 2011, Tech. Rep
[4]  
Awad SF, 2015, INVESTIGATING UNPUB
[5]   When individual behaviour matters: homogeneous and network models in epidemiology [J].
Bansal, Shweta ;
Grenfell, Bryan T. ;
Meyers, Lauren Ancel .
JOURNAL OF THE ROYAL SOCIETY INTERFACE, 2007, 4 (16) :879-891
[6]   Effect of variable transmission rate on the dynamics of HIV in sub-Saharan Africa [J].
Cuadros, Diego F. ;
Crowley, Philip H. ;
Augustine, Ben ;
Stewart, Sarah L. ;
Garcia-Ramos, Gisela .
BMC INFECTIOUS DISEASES, 2011, 11
[7]  
Drummond M.F., 1999, METHODS EC EVALUATIO, V2nd
[8]   Degree distributions in sexual networks: A framework for evaluating evidence [J].
Hamilton, Deven T. ;
Handcock, Mark S. ;
Morris, Martina .
SEXUALLY TRANSMITTED DISEASES, 2008, 35 (01) :30-40
[9]   Likelihood-based inference for stochastic models of sexual network formation [J].
Handcock, MS ;
Jones, JH .
THEORETICAL POPULATION BIOLOGY, 2004, 65 (04) :413-422
[10]   Achieving the millennium development goals for health - Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries [J].
Hogan, DR ;
Baltussen, R ;
Hayashi, C ;
Lauer, JA ;
Salomon, JA .
BRITISH MEDICAL JOURNAL, 2005, 331 (7530) :1431-1435